Waters Corporation Announces The Purchase Of UPLC/MS Systems By The National Cancer Institute For Advanced Metabolomics Research

Waters Corporation (NYSE: WAT) announced that the National Cancer Institute’s Center for Cancer Research in Bethesda, Md., purchased Waters(R) ACQUITY UPLC(R)/Synapt High Definition MS (HDMS(TM)) and Waters ACQUITY(R) UPLC/Xevo(TM) TQ MS Systems for its metabolomics research programs. The research is aimed at discovering small molecule metabolites, or biomarkers, associated with cancer susceptibility and diagnosis, treatment efficacy and the adverse effects of medicines and other chemicals.

More: continued here

Filed under: Cancer on April 3rd, 2009